The Sestrin family (SESN1, SESN2, SESN3) represents a group of highly conserved stress-responsive proteins that serve as critical integrators of cellular homeostasis pathways[@sestrin2024]. Originally discovered as p53-induced genes, Sestrins have emerged as master regulators of mTOR signaling, autophagy, oxidative stress response, and mitochondrial function. In the context of neurodegeneration, Sestrins link nutrient sensing, metabolic stress, and proteostasis—making them compelling therapeutic targets for Alzheimer's disease, Parkinson's disease, and related disorders[@sestrins2024].
The Sestrin family consists of three isoforms with distinct but overlapping functions:
- Sestrin 1 (SESN1): Ubiquitously expressed, primarily p53-regulated, involved in oxidative stress response
- Sestrin 2 (SESN2): Highly stress-inducible through ATF4, localized to cytoplasm, primary amino acid sensor
- Sestrin 3 (SESN3): Widely expressed, regulated by mTOR and FoxO, involved in metabolic homeostasis
flowchart TD
A["Amino Acids<br/>Growth Factors"] --> B["GATOR2 Complex"]
B --> C{"Sestrin Binding"}
C -->|"Inhibition"| D["mTORC1 Activation"]
C -->|"Activation"| E["mTORC1 Inhibition"]
E --> F["S6K1 Inhibition"]
F --> G["Autophagy Initiation"]
G --> H["Proteostasis Restoration"]
C --> I["AMPK Activation"]
I --> J["FoxO Transcription<br/>Factor Activation"]
J --> K["Antioxidant Gene<br/>Expression"]
K --> L["Nrf2 Pathway<br/>Activation"]
L --> M["HO-1, NQO1<br/>Antioxidants"]
N["DNA Damage<br/>Oxidative Stress"] --> O["p53/ATF4<br/>Activation"]
O --> P["Sestrin Expression"]
P --> Q["Mitochondrial<br/>Biogenesis"]
Q --> R["PGC-1α<br/>Activation"]
S["ER Stress<br/>Proteotoxicity"] --> T["ATF4/CHOP"]
T --> U["Sestrin Expression"]
U --> V["Autophagy<br/>Enhancement"]
V --> W["Protein Aggregate<br/>Clearance"]
X["Neurodegeneration<br/>Aβ, α-Syn, Tau"] --> Y["Pathological<br/>Stress"]
Y --> Z["Sestrin<br/>Depletion"]
Z --> aa["mTOR<br/>Hyperactivation"]
aa --> bb["Autophagy<br/>Blockade"]
bb --> cc["Synaptic<br/>Dysfunction"]
cc --> dd["Neuronal<br/>Death"]
style Z fill:#ffcdd2,stroke:#b71c1c
style aa fill:#ffcdd2,stroke:#b71c1c
style cc fill:#ffcdd2,stroke:#b71c1c
style dd fill:#ffcdd2,stroke:#b71c1c
| Protein |
Gene |
Chromosome |
Key Functions |
Expression |
| Sestrin 1 |
SESN1 |
19q13.12 |
p53-regulated, oxidative stress response |
Ubiquitous |
| Sestrin 2 |
SESN2 |
6p21.1 |
Amino acid sensing, GATOR2 interaction |
Inducible |
| Sestrin 3 |
SESN3 |
11p11.2 |
mTORC1 regulation, metabolic homeostasis |
Wide |
- mTORC1: Mammalian target of rapamycin complex 1, central regulator of growth and metabolism[@mtorc2022]
- AMPK: AMP-activated protein kinase, energy sensor and autophagy activator
- FoxO: Forkhead box O transcription factors, stress resistance and longevity
- PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, mitochondrial biogenesis
- Nrf2: Nuclear factor erythroid 2-related factor 2, antioxidant response
- GATOR2: GAP activity toward Rag GTPases 2, amino acid sensing complex[@gator2022]
- GATOR1: GAP complex providing baseline mTORC1 inhibition
- PAQR3: Progestin and adipoQ receptor 3, scaffolds Sestrin2-mTOR interaction
- CASTOR1: Cytosolic arginine sensor for mTORC1 regulation
In Alzheimer's disease, Sestrin expression is significantly downregulated in vulnerable brain regions[@sestad2023]. Amyloid-beta oligomers induce oxidative stress that depletes Sestrin levels through p53-independent mechanisms. The loss of Sestrin function contributes to:
- mTORC1 hyperactivation: Sestrin normally inhibits mTORC1; its depletion leads to constitutive activation
- Autophagy impairment: mTORC1 overactivity blocks autophagy initiation, preventing clearance of protein aggregates
- Synaptic plasticity deficits: mTORC1 dysregulation affects local translation at synapses
- Tau pathology: Autophagy blockade allows hyperphosphorylated tau to accumulate[@sestdb2023]
Sestrin modulators represent promising therapeutic approaches for AD:
- Sestrin2 agonists: Small molecules that stabilize Sestrin2-GATOR2 interaction
- Gene therapy: AAV-SESN2 delivery to CNS
- Peptide mimetics: Bioactive Sestrin fragments
Sestrins protect against alpha-synuclein pathology through multiple mechanisms:
- Autophagy enhancement: Sestrin2 promotes mitophagy to clear damaged mitochondria
- Oxidative stress mitigation: Nrf2 pathway activation reduces ROS damage
- Dopaminergic neuron survival: Sestrin3 specifically protects substantia nigra neurons
Parkinson's disease is characterized by mitochondrial complex I deficiency. Sestrins help maintain mitochondrial health through:
- PGC-1α activation: Promotes mitochondrial biogenesis
- Mitophagy regulation: Clears dysfunctional mitochondria
- Metabolic adaptation: Helps neurons survive energy stress
- Parkin-independent mitophagy: Sestrin2 can trigger mitophagy via alternative pathways
In ALS, Sestrin expression is reduced in motor neurons, contributing to:
- mTORC1 dysregulation: Altered growth factor signaling
- Autophagy blockade: Accumulation of protein aggregates (TDP-43, SOD1)
- Oxidative stress: Increased vulnerability to ROS
- ER stress amplification: Synergistic proteostasis failure
- Sestrin2 overexpression: Gene therapy approaches in development
- mTOR modulation: Rapamycin shows benefit in ALS models
- Combination therapy: Sestrin activators with autophagy inducers
¶ Oxidative Stress and Sestrins
Sestrins play a central role in oxidative stress response:
Nrf2 Pathway Activation:
- Sestrin2 binds to and inhibits Keap1
- Nrf2 translocates to nucleus
- Antioxidant gene expression (HO-1, NQO1, GCLC)
- Cellular redox homeostasis
FoxO Transcription Factor Regulation:
- Sestrin activates FoxO through AMPK
- FoxO drives antioxidant gene expression
-extends neuronal survival under stress
- Links metabolic status to stress resistance
Sestrins are highly induced by various stresses and decline with age. This age-related Sestrin decline creates a permissive environment for neurodegeneration:
- Reduced stress resistance: Diminished ability to cope with insults
- mTORC1 dysregulation: Contributes to age-related protein aggregation
- Metabolic dysfunction: Altered nutrient sensing
- Mitochondrial decline: Impaired mitophagy and biogenesis
| Strategy |
Approach |
Status |
Disease |
| Sestrin2 agonists |
Small molecule activators |
Preclinical |
AD, PD |
| Gene therapy |
AAV-SESN2 delivery |
Phase I/II |
AD, PD |
| Peptide mimetics |
Bioactive fragments |
Preclinical |
AD |
| Protein delivery |
Recombinant Sestrin |
Discovery |
PD |
| Strategy |
Approach |
Status |
Disease |
| mTOR inhibitors |
Rapamycin, everolimus |
Approved |
PD, ALS |
| AMPK activators |
Metformin, AICAR |
Approved |
AD |
| Nrf2 activators |
Sulforaphane, oltipraz |
Phase II |
AD |
| Autophagy inducers |
Trehalose, lithium |
Phase II |
PD |
- Rapamycin + Sestrin activators: Multi-target proteostasis activation
- Metformin + Nrf2 activators: Metabolic and antioxidant enhancement
- Gene therapy + small molecules: Sustained expression with pharmacologic boost
¶ Biomarkers and Clinical Relevance
- Sestrin2 levels: Measurable in CSF, potential progression marker
- Genetic variants: SESN2 polymorphisms associated with AD risk
- Therapeutic monitoring: Sestrin levels may predict treatment response
- Sestrin2 inversely correlates with cognitive decline in AD
- SESN2 expression reduced in PD substantia nigra
- Sestrin decline precedes clinical symptoms in some cases
- Polymorphisms affect age of onset in rare cases
- Sestrin isoform specificity: Which isoform is most therapeutically relevant?
- Delivery challenges: How to achieve adequate CNS penetration?
- Biomarker validation: Can sestrin predict treatment response?
- Combination approaches: Which combinations show synergy?
¶ Clinical Trial Landscape
- Sestrin2 modulators: Preclinical development accelerating
- Gene therapy: AAV-SESN2 in IND-enabling studies
- Repurposing opportunities: Existing drugs with sestrin effects
- Sestrin2 and autophagy: New mechanisms linking Sestrin2 to selective autophagy in AD models (2024)
- Sestrins in PD: Evidence for Sestrin3 neuroprotection in dopaminergic neurons (2024)
- GATOR complex: Structural insights into Sestrin-GATOR interaction (2024)
- Therapeutic development: Sestrin2 activators showing promise in preclinical models (2024)